Medical Oncologist
Medicines
How much do zoledronic acid and denosumab actually help? The numbers explained
Zoledronic acid and denosumab lower bone problems in bone metastases without lengthening survival, prevent bone loss and fractures on hormone treatment, and, for zoledronic acid, modestly lower recurrence in postmenopausal early breast cancer. This page explains the key findings in plain words, relative and absolute numbers, and how to weigh the benefit.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How much do zoledronic acid and denosumab actually help?
- What the benefit looks like in each setting
- Key findings in plain words
- The vocabulary, in plain language
- Reading the numbers sensibly
- Why relative and absolute numbers both matter
- What benefit can mean in daily life
- Questions to ask your oncologist
- What people assume about the benefit
- Common questions about the benefit of bone-directed medicines
The short answer
How much do zoledronic acid and denosumab actually help?
The benefit of bone-directed medicines depends on why they are used, so it helps to look at each situation separately. For breast cancer that has spread to bone, bone medicines lower the risk of bone problems such as fractures, spinal cord pressure, and the need for radiotherapy or surgery to bone. Pooled analyses suggest bisphosphonates reduce these problems by a meaningful amount compared with no bone medicine, and in a large head-to-head study denosumab lowered the rate by roughly a fifth more than zoledronic acid and delayed the first bone problem somewhat longer. They can also help with bone pain and delay it getting worse. However, neither medicine helped people with bone metastases live longer. For bone protection during hormone treatment, both prevent the bone loss that aromatase inhibitors and early menopause cause, and in one large study denosumab roughly halved the number of fractures in women taking aromatase inhibitors. For postmenopausal women with early breast cancer, a large analysis combining many trials found that bisphosphonates reduced the chance of cancer returning in bone by roughly a quarter, and lowered the chance of dying from breast cancer by roughly a sixth over ten years. In absolute terms that means a few fewer women in every hundred dying of breast cancer. No such benefit was seen in premenopausal women with working ovaries, and denosumab did not show it. For high blood calcium caused by cancer, zoledronic acid brings calcium back towards normal in most people within days.
Bone metastases
Fewer and later bone problems, but no longer survival.
Bone protection
Less bone loss and fewer fractures on hormone treatment.
Early breast cancer after menopause
A modest drop in bone recurrence and breast cancer deaths with bisphosphonates.
This page gives general information only. Your oncologist can relate these findings to you.By situation
What the benefit looks like in each setting
The same medicine can offer quite different gains depending on the reason for use.
Cancer in the bones
Fewer fractures, less need for bone radiotherapy or surgery, and help with pain. No proven survival gain.
Hormone treatment bone loss
Bone density is maintained or improved, and fractures are reduced.
Calcium, vitamin D and exercise add to the effect.Early breast cancer after menopause
Zoledronic acid lowers bone recurrence and breast cancer deaths by a modest amount.
High blood calcium
Zoledronic acid brings calcium down in most people within days.
Where benefit is not shown
- Survival in bone metastases
- Premenopausal early cancer with working ovaries
- Denosumab as an anti-recurrence treatment
The results
Key findings in plain words
Question
What studies showed
Denosumab against zoledronic acid in bone metastases
Bone problems lowered by roughly a fifth more, with similar survival
Denosumab on aromatase inhibitors
Roughly half as many fractures as without it
Bisphosphonates after menopause, early cancer
Bone recurrence lower by roughly a quarter
Breast cancer deaths over ten years
Lower by roughly a sixth, a few fewer women in every hundred
Premenopausal women with working ovaries
No clear benefit on recurrence
Words you will hear
The vocabulary, in plain language
- Relative reduction
- How much a risk falls compared with its starting level, such as by a quarter.
- Absolute reduction
- How many fewer people in every hundred have a problem.
- Meta-analysis
- A study that combines results from many trials to give a clearer answer.
- Skeletal-related event
- A bone problem such as a fracture, spinal cord pressure or bone radiotherapy.
- Bone recurrence
- Breast cancer returning in the bones after earlier treatment.
- Overall survival
- How long people live, whatever happens to the cancer.
Being straight with you
Reading the numbers sensibly
These findings come from large, reliable studies, but they still need careful reading.
Relative and absolute gains differ
A quarter fewer bone recurrences sounds large, but in absolute terms it means a small number of women in every hundred.
Your baseline risk matters
Women with a higher risk of recurrence gain more in absolute terms than those with a low risk.
Benefits sit alongside risks
Uncommon side effects, such as jaw problems, are weighed against these gains.
What this page cannot tell you
It cannot calculate your own benefit. Your oncologist can estimate it using your cancer details.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Understanding numbers
Why relative and absolute numbers both matter
Medical results are often reported in two ways, and knowing the difference prevents confusion.
Relative numbers
These describe how much a risk falls compared with no treatment. They are useful for comparing treatments.
Absolute numbers
These show how many people in every hundred actually benefit. They help you judge whether a gain is worth it for you.
An example
If a risk falls from ten in a hundred to seven in a hundred, the relative reduction is about a third, but the absolute reduction is three in a hundred.
Beyond the numbers
What benefit can mean in daily life
Protecting bone often shows up as problems that never happen, which can make the benefit easy to overlook.
Staying mobile
Avoiding a fracture can mean keeping your independence, work and daily routines.
Fewer emergencies
Lower rates of spinal cord pressure and high calcium mean fewer urgent hospital stays.
Peace of mind
For some, knowing bones are protected during hormone treatment eases worry about falls and fractures.
Your conversation
Questions to ask your oncologist
These questions can help turn study results into a conversation about you.
About my situation
Why do I need a bone medicine, and what benefit might I expect in my case?
About risk
What is my risk of jaw problems or low calcium, and how can I reduce it?
About duration
How long will treatment last, and when will we review whether I still need it?
Commonly believed
What people assume about the benefit
Bone injections help people with bone metastases live longer.
They reduce bone problems but have not been shown to lengthen survival.
Every woman with early breast cancer benefits.
The recurrence benefit was seen after menopause or with ovarian suppression.
If no fracture happens, the medicine did nothing.
Prevention works by making problems less likely, so success is often invisible.
A quarter fewer recurrences means a quarter of women are helped.
Relative and absolute numbers differ. Ask how many in every hundred benefit.
Questions we are asked
Common questions about the benefit of bone-directed medicines
Will zoledronic acid stop my early breast cancer coming back?
It cannot stop recurrence for certain. For postmenopausal women, it slightly lowers the chance of cancer returning in bone and of dying from breast cancer. The absolute gain is a few women in every hundred. Your oncologist can estimate your own likely benefit.
Why does menopause matter for the benefit?
Researchers think low oestrogen changes the bone environment in a way that lets bisphosphonates make it less welcoming to stray cancer cells. The benefit appeared in women after natural menopause or with ovarian suppression, but not in those with working ovaries.
If I have bone metastases, will these medicines help me live longer?
They have not been shown to lengthen survival in bone metastases. Their value is in lowering and delaying fractures, spinal cord pressure, high calcium and the need for bone radiotherapy or surgery, which protects quality of life.
Do they reduce bone pain?
They can help some people with bone pain and may delay pain getting worse. They are not fast painkillers, so painkillers and radiotherapy to painful areas remain important. Tell your team if pain is not well controlled.
How much does denosumab reduce fractures on aromatase inhibitors?
In a large study of women taking aromatase inhibitors, denosumab roughly halved the number of fractures compared with no denosumab. Stopping it needs a plan, because bone loss can speed up when it wears off.
Is denosumab better than zoledronic acid?
In bone metastases, denosumab lowered bone problems a little more, with similar survival. In early breast cancer, only zoledronic acid lowers recurrence. Kidneys, cost and plans for stopping also matter, so neither is best for everyone.
How would I know if it is working?
For bone protection, DEXA scans show whether bone density is holding steady. For bone metastases and early cancer, benefit shows as problems that do not happen, so there is no single test. Your team reviews your overall progress.
Is the benefit worth the risks?
For most people with bone metastases or significant bone loss, the benefits clearly outweigh the uncommon risks. For early breast cancer, the gain is smaller, so the balance is more personal. Discuss your priorities with your oncologist.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- The Lancet — Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- Journal of Clinical Oncology — Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer
- The Lancet — Adjuvant denosumab in breast cancer (ABCSG-18)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.